Psychiatr News August 4, 2006
Volume 41, Number 15, page 21
© 2006 American Psychiatric Association
Erratum
In an article in the July 7 issue on monitoring adverse effects of
antipsychotics, it was noted that Pfizer Inc. is funding a large international
study known as the Ziprasidone Observational Study of Cardiac Outcomes. Two
details about the study were incorrect.
The study will assess the cardiovascular safety profile of Pfizer's Geodon
brand of ziprasidone compared with olanzapine (Eli Lilly's Zyprexa) only, not
several other antipsychotics.
The study is being led by Brian Strom, M.D., M.P.H., director of the Center
for Clinical Epidemiology and Biostatistics at the University of Pennsylvania
School of Medicine, not by John Kane, M.D. Kane is a participating researcher
in the study. 
Get information about faster international access.
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
